Parkinson's disease, L-Dopa and "express'' saccades: Superior colliculus dyskinesias?

被引：12
|
作者：
Cubizolle, Stephanie [1 ,2 ,3 ]
Damon-Perriere, Nathalie [2 ,4 ]
Dupouy, Sandrine [1 ,2 ]
Foubert-Samier, Alexandra [1 ,2 ,5 ]
Tison, Francois [1 ,2 ,3 ]
机构：
[1] CHU Bordeaux, Serv Neurol, F-330604 Pessac, France
[2] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, F-33076 Bordeaux, France
[3] Univ Bordeaux 2, Neurophysiol Lab, CNRS, Inst Malad Neurodegenerat,UMR 5293, F-33076 Bordeaux, France
[4] CHU Bordeaux, F-33000 Bordeaux, France
[5] Univ Bordeaux, INSERM, ISPED, U897, F-33076 Bordeaux, France
来源：
CLINICAL NEUROPHYSIOLOGY | 2014年 / 125卷 / 03期
关键词：
PERFORMANCE;
D O I：
10.1016/j.clinph.2013.06.188
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：647 / 648
页数：2
相关论文
共 50 条
  • [41] Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose
    Ondo, William
    Coss, Pablo
    Christie, Melissa
    Pascual, Belen
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (01) : 153 - 156
  • [42] Suppression of L-DOPA induced dyskinesias in advanced Parkinson's disease by continuous subcutaneous infusions of apomorphine - ten years of experience
    Kanovsky, P.
    Bares, M.
    Rektorova, I.
    Kubova, D.
    Nestrasil, I.
    Farnikova, K.
    Ressner, P.
    Rektor, I.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S119 - S120
  • [43] Suppression of L-DOPA induced dyskinesias in advanced Parkinson's disease by continuous subcutaneous infusions of apomorphine - 10 years of experience
    Kanovsky, P.
    Bares, M.
    Farnikova, K.
    Nestrasil, I.
    Kubova, D.
    Rektorova, I.
    Rektor, I.
    Ressner, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 113 - 113
  • [44] Interactions between cognition, depression and L-dopa in Parkinson's disease
    Degroot, C.
    Bruneau, M. A.
    Mejia-Constain, B.
    Bedetti, C.
    Monchi, O.
    MOVEMENT DISORDERS, 2012, 27 : S280 - S280
  • [45] L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning
    Chagraoui, Abdeslam
    Boulain, Marie
    Juvin, Laurent
    Anouar, Youssef
    Barriere, Gregory
    De Deurwaerdere, Philippe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [46] L-dopa plasma levels and executive functions in Parkinson's disease
    Albani, G.
    Cattaldo, S.
    Mori, I.
    Pignatti, R.
    Pradotto, L.
    Mauro, A.
    MOVEMENT DISORDERS, 2009, 24 : S289 - S289
  • [47] The Effect of L-dopa on Postural Stability in Parkinson's Disease Patients
    Wilczynski, Jacek
    Habik, Natalia
    APPLIED SCIENCES-BASEL, 2019, 9 (03):
  • [48] Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients
    O. Bartošová
    C. Bonnet
    O. Ulmanová
    M. Šíma
    F. Perlík
    E. Růžička
    O. Slanař
    Journal of Neural Transmission, 2018, 125 : 699 - 703
  • [49] L-dopa therapy for Parkinson's disease: Past, present, and future
    Nagatsu, Toshiharu
    Sawada, Makoto
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S3 - S8
  • [50] L-dopa related hyperhomocysteinemia and development of dementia in Parkinson's disease
    dell'Aquila, C.
    Zoccolella, S.
    Mascolo, L.
    Abruzzese, G.
    Antonini, A.
    Bonuccelli, U.
    Dlazio, G.
    Pacchetti, C.
    Lamberti, P.
    MOVEMENT DISORDERS, 2008, 23 (01) : S249 - S249
12345